Agios Pharmaceuticals (AGIO) Q4 2025 earnings summary

Executive summary

• Achieved strong commercial execution in Q4 and FY 2025, with PYRUKYND delivering $20M in Q4 and $54M for the year, reflecting robust year-over-year growth and successful launches in rare hematology indications.

• FDA approval and U.S. launch of ACTIVASE/AQVESME (mitapivat) for thalassemia in December 2025, with early positive physician and patient engagement and 44 prescriptions through January 2026.

• Advanced pipeline with key milestones, including completion of enrollment in Phase 2 tebapivat trial for sickle cell disease, pre-sNDA meeting for mitapivat in sickle cell disease scheduled for Q1 2026, and anticipated data readouts for tebapivat, AG-236, and AG-181 in 2026.

• Maintained robust financial discipline, ending 2025 with $1.2B in cash, cash equivalents, and marketable securities, providing flexibility for launches and pipeline advancement.

• Clear path to profitability based on thalassemia and PK deficiency franchises, with disciplined capital allocation and operational efficiency.

Financial highlights

• Q4 2025 PYRUKYND net revenue was $20M, up 86% year-over-year and 55% sequentially; FY 2025 net revenues were $54M, up 48% from FY 2024.

• U.S. Q4 PYRUKYND revenue was $16M; ex-U.S. Q4 revenue was $4M, mainly from inventory stocking in Europe.

• FY 2025 net loss was $(412.8)M, compared to net income of $673.7M in FY 2024, which included significant one-time gains.

• Cost of sales for Q4 2025 was $1.9M; R&D expenses were $88.1M in Q4 and $339.5M for FY 2025; SG&A expenses were $51.6M in Q4 and $180.3M for FY 2025.

• Cash, cash equivalents, and marketable securities at $1.2B at year-end 2025.

Outlook and guidance

• 2026 U.S. PK deficiency revenue expected in the range of $45–$50M.

• Operating expenses in 2026 anticipated to be roughly flat with 2025, with potential for greater efficiencies beyond 2026.

• Anticipate strong catalyst flow in 2026, including regulatory milestones and topline data readouts for multiple pipeline assets.

• Ex-U.S. revenue expected to decrease in Q1 2026 due to prior inventory stocking.

• Cash position expected to support commercial launches and pipeline expansion.